Mayo Collaborative Services v. Prometheus Laboratories, Inc.

Mayo Collaborative Services v. Prometheus Laboratories, Inc. was a 2012 decision of the Supreme Court of the United States that addressed patent eligibility of medical diagnostic methods. The Court held that certain processes that apply natural correlations are not patentable under the Patent Act of 1952, in a unanimous opinion authored by Justice Stephen Breyer. The case influenced patent doctrine for biotechnology, pharmaceutical diagnostics, and personalized medicine.

Background

Prometheus Laboratories, Inc. was the assignee of patents claiming methods for optimizing treatment of patients taking thiopurine drugs; the claimed steps included administering a drug, measuring metabolite levels, and adjusting dosage based on detected metabolite concentrations. The dispute arose after Mayo Clinic's laboratories performed similar tests and published related protocols; Mayo Collaborative Services challenged the patents in federal court, invoking the statutory framework and precedents including Diamond v. Chakrabarty and Gottschalk v. Benson. The Federal Circuit affirmed the patents initially, relying on differences from prior decisions, prompting review by the Supreme Court. Parties and amici included actors such as Association for Molecular Pathology, American Medical Association, Biotechnology Industry Organization, and AARP.

Legal Issues

The principal legal issue was whether claims reciting a process that applies a natural correlation between metabolite levels and therapeutic efficacy or toxicity constitute patent-eligible subject matter under 35 U.S.C. § 101. Secondary issues implicated precedents on patentable subject matter such as Parker v. Flook, Mayo Collaborative Services v. Prometheus Laboratories, Inc. (the present case name was the grant vehicle), and the interplay with patentability doctrines from Diamond v. Diehr and Gottschalk v. Benson. The case raised questions about the scope of patent protection for methods in clinical chemistry, genomics, and diagnostic testing, and whether statutory text or judicial exceptions should control eligibility determinations.

Supreme Court Decision

In a unanimous decision delivered by Justice Stephen Breyer, the Court held that Prometheus' patent claims effectively monopolized a law of nature—specifically, the relation between metabolite concentration and drug toxicity or efficacy—and that adding conventional steps such as administering a drug and measuring metabolite levels did not transform the claims into patent-eligible applications. The Court reversed the Federal Circuit and invalidated the asserted claims as directed to patent-ineligible subject matter under 35 U.S.C. § 101, while reiterating that not all claims involving medical practices are excluded from patent protection.

Reasoning and Legal Standards

The opinion applied a two-step framework derived from prior decisions: first, determine whether the claim is directed to a law of nature, natural phenomenon, or abstract idea as found in Parker v. Flook and Gottschalk v. Benson; second, assess whether additional claim elements transform the nature of the claim into a patent-eligible application, as in Diamond v. Diehr. Justice Breyer emphasized that granting a patent that effectively monopolizes a basic scientific relationship would impede rather than promote the Constitution's objective to "promote the Progress of Science and useful Arts" under Article I. The Court examined claim elements and concluded that steps such as "administering" and "determining" were well-understood, routine, and conventional, lacking an inventive concept to render the law of nature patentable—a reasoning related to tests discussed in Alice Corp. v. CLS Bank International though that decision postdates the procedural development of § 101 jurisprudence. The Court also addressed concerns raised by United States Patent and Trademark Office practice and the potential chilling effect on medical innovation, urging careful tailoring of patent claims but declining to adopt per se rules that medical practitioners could not obtain patents.

Impact and Subsequent Developments

The decision had immediate and significant effects on patent litigation and prosecution in biotechnology, pharmaceuticals, and medical diagnostics. Courts and the United States Court of Appeals for the Federal Circuit applied Mayo to invalidate patents that were seen as claiming natural laws without inventive application, influencing decisions involving genes, biomarkers, and diagnostic methods, and interacting with later rulings such as Alice Corp. v. CLS Bank International and Association for Molecular Pathology v. Myriad Genetics, Inc.. The ruling prompted changes in patent drafting strategies within firms like Genentech, AbbVie, and Roche and affected policy discussions at institutions including the United States Patent and Trademark Office, National Institutes of Health, and the World Intellectual Property Organization. Legislative and academic responses involved analyses from entities such as Congressional Research Service, commentators at Stanford University, Harvard University, and think tanks like Brookings Institution and American Enterprise Institute. The decision continues to inform debates over incentives for personalized medicine, the balance between proprietary rights and clinical practice, and the boundaries of patentable subject matter under 35 U.S.C. § 101.

Category:United States Supreme Court cases Category:United States patent case law Category:2012 in United States case law